FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215637029> ?p ?o ?g. }

• W3215637029 endingPage "2243" @default.
• W3215637029 startingPage "2243" @default.
• W3215637029 abstract "Abstract The clinical manifestations, management, and prognosis of acute promyelocytic leukemia (APL) are distinctive in acute myeloid leukemia (AML). Administration of all-trans retinoic acid (ATRA) and arsenic agents have greatly improved the outcome of APL from the most lethal to the most curable subtype AML. Unfortunately, relapse is still observed. And in the case of combined medication with ATRA and arsenic, the resistance mutation spectrum of PML-RARA is far from being revealed. We retrospectively analyzed 40 APL patients that admitted to our hospital from Jan. 2013 to Jul. 2020. There were 21 males and 19 females, aged 6-65 years (median age 31.5), and follow-up time was 3-210 months (median time 58.85 months). There were 3 cases that developed secondary tumors, although APL remission has been achieved. One developed refractory AML with KMT2A-MLLT3 fusion during the consolidation treatment one year after the diagnosis of APL. One case relapsed with APL 5 years after the initial diagnosis, and she developed refractory AML with RUNX1-MECOM fusion 3.5 years more after enduring multiple relapses and treatment courses. Another case developed AML-M2 3.5 years after the initial diagnosis of APL, and achieved sustained remission again through allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 8 cases came to our hospital at the initial onset of APL, and 1 came during remission. All these cases got sustained remission through combined triple therapy (ATRA, arsenic, and chemotherapy), with the follow-up time of 3 to 37 months (median 20.5 months). No PML-RARA resistant mutation was detected in these 9 cases. A total of 28 cases came to our hospital after APL relapse. The time from APL onset to the first relapse was 9-189 months (median 34 months). PML-RARA resistance mutations were detected in 9 cases, including 8 cases that carry single RARA mutations each, and 1 case that relapsed with multiple extramedullary infiltrations carry quadruple mutations (PML S214L-A216T and RARA R276W-H298N) (Figure 1a and b). A total of 4 cases underwent allo-HSCT after APL relapse. One of them relapsed 6 months after allo-HSCT, and the other 3 got sustained remission with the follow-up time of 47, 39, and 52 months, respectively. There were 2 cases relapsed after maintaining sustained remission for more than 5 years. One was a 58-year-old male who achieved sustained remission after 2.5 years of combined triple therapy. However, APL recurred 16 years after the primary diagnosis. He achieved remission again and now underwent the consolidation course of combined triple therapy. Another was a 23-year-old male who achieved sustained remission after combined arsenic and chemotherapy, but APL relapsed 75 months after the primary diagnosis. He was resistant to combined triple therapy and achieved remission through allo-HSCT. We failed to retrieve archived specimens at the first onset of APL for genomic variation comparison with the second onset. Therefore, we could not determine whether these two cases were relapsed from the original APL or developed another APL. Although we have achieved a high remission rate and long-term survival for APL through combined triple therapy, relapse and secondary tumors still occur in some cases. Especially for cases that endure heavy treatment, genomic toxicity may promote the oncogenesis of secondary tumors. Also, APL may recur over 5 years after the primary diagnosis and sustained remission. Whether there were inherited predisposing factors in these cases is worthy of further investigation. The incidence of PML and RARA resistant mutations in cases resistance for ATRA and arsenic is not very high. This may be related to the combination use of chemotherapeutic drugs and suggests underlying resistance mechanisms. Although both ATRA and arsenic were used in most cases, the incidence of ATRA resistance mutations is significantly higher than that of arsenic, which might attribute to the sparse interaction sites of arsenic and PML. A better combination strategy of arsenic, ATRA, with or without chemotherapy is worthy of further investigation to reduce the incidence of secondary tumors and relapse. Adhering to a systematically planed treatment course is essential for acquiring rapid remission and reduction of relapse. Treatment compliance should be paid attention to guaranteed, especially during the oral administration courses outside the hospital. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W3215637029 created "2021-12-06" @default.
• W3215637029 creator A5002661071 @default.
• W3215637029 creator A5017390213 @default.
• W3215637029 creator A5020424453 @default.
• W3215637029 creator A5036645166 @default.
• W3215637029 creator A5037418578 @default.
• W3215637029 creator A5055550921 @default.
• W3215637029 creator A5071844040 @default.
• W3215637029 creator A5081336771 @default.
• W3215637029 date "2021-11-05" @default.
• W3215637029 modified "2023-10-16" @default.
• W3215637029 title "Relapse Analysis and Resistance Mutations of PML-Rara Fusion Gene in Acute Promyelocytic Leukemia Patients Treated with All-Trans Retinoic Acid and Arsenic" @default.
• W3215637029 doi "https://doi.org/10.1182/blood-2021-149404" @default.
• W3215637029 hasPublicationYear "2021" @default.
• W3215637029 type Work @default.
• W3215637029 sameAs 3215637029 @default.
• W3215637029 citedByCount "0" @default.
• W3215637029 crossrefType "journal-article" @default.
• W3215637029 hasAuthorship W3215637029A5002661071 @default.
• W3215637029 hasAuthorship W3215637029A5017390213 @default.
• W3215637029 hasAuthorship W3215637029A5020424453 @default.
• W3215637029 hasAuthorship W3215637029A5036645166 @default.
• W3215637029 hasAuthorship W3215637029A5037418578 @default.
• W3215637029 hasAuthorship W3215637029A5055550921 @default.
• W3215637029 hasAuthorship W3215637029A5071844040 @default.
• W3215637029 hasAuthorship W3215637029A5081336771 @default.
• W3215637029 hasConcept C104317684 @default.
• W3215637029 hasConcept C126322002 @default.
• W3215637029 hasConcept C141071460 @default.
• W3215637029 hasConcept C143998085 @default.
• W3215637029 hasConcept C187212893 @default.
• W3215637029 hasConcept C2776601000 @default.
• W3215637029 hasConcept C2776694085 @default.
• W3215637029 hasConcept C2777408962 @default.
• W3215637029 hasConcept C2778461978 @default.
• W3215637029 hasConcept C2780775027 @default.
• W3215637029 hasConcept C2781121885 @default.
• W3215637029 hasConcept C2911091166 @default.
• W3215637029 hasConcept C55493867 @default.
• W3215637029 hasConcept C71924100 @default.
• W3215637029 hasConcept C86803240 @default.
• W3215637029 hasConcept C90924648 @default.
• W3215637029 hasConceptScore W3215637029C104317684 @default.
• W3215637029 hasConceptScore W3215637029C126322002 @default.
• W3215637029 hasConceptScore W3215637029C141071460 @default.
• W3215637029 hasConceptScore W3215637029C143998085 @default.
• W3215637029 hasConceptScore W3215637029C187212893 @default.
• W3215637029 hasConceptScore W3215637029C2776601000 @default.
• W3215637029 hasConceptScore W3215637029C2776694085 @default.
• W3215637029 hasConceptScore W3215637029C2777408962 @default.
• W3215637029 hasConceptScore W3215637029C2778461978 @default.
• W3215637029 hasConceptScore W3215637029C2780775027 @default.
• W3215637029 hasConceptScore W3215637029C2781121885 @default.
• W3215637029 hasConceptScore W3215637029C2911091166 @default.
• W3215637029 hasConceptScore W3215637029C55493867 @default.
• W3215637029 hasConceptScore W3215637029C71924100 @default.
• W3215637029 hasConceptScore W3215637029C86803240 @default.
• W3215637029 hasConceptScore W3215637029C90924648 @default.
• W3215637029 hasIssue "Supplement 1" @default.
• W3215637029 hasLocation W32156370291 @default.
• W3215637029 hasOpenAccess W3215637029 @default.
• W3215637029 hasPrimaryLocation W32156370291 @default.
• W3215637029 hasRelatedWork W2074118757 @default.
• W3215637029 hasRelatedWork W2271311441 @default.
• W3215637029 hasRelatedWork W2280027195 @default.
• W3215637029 hasRelatedWork W2357142827 @default.
• W3215637029 hasRelatedWork W2366793411 @default.
• W3215637029 hasRelatedWork W2376376709 @default.
• W3215637029 hasRelatedWork W2378479985 @default.
• W3215637029 hasRelatedWork W2559649769 @default.
• W3215637029 hasRelatedWork W2600735778 @default.
• W3215637029 hasRelatedWork W2893092605 @default.
• W3215637029 hasVolume "138" @default.
• W3215637029 isParatext "false" @default.
• W3215637029 isRetracted "false" @default.
• W3215637029 magId "3215637029" @default.
• W3215637029 workType "article" @default.